Precision Biosciences (DTIL) Stock News
$DTIL · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Precision Biosciences (DTIL) in the past 30 days. BORSA’s news read on DTIL is bullish at 58/100, unchanged over 24 hours, based on 1 company event over the past 30 days. Precision Biosciences’ next earnings report is scheduled for Monday, Nov 2.
The wire on $DTIL
newest first · updated · direct subject stories onlyPrecision BioSciences PBGENE-HBV selected for late-breaking oral at AASLD
Precision BioSciences (DTIL) announced its PBGENE-HBV gene editing therapy for chronic hepatitis B was selected for a late-breaking oral presentation at AASLD The Liver Meeting 2026. The presentation is scheduled for Nov 8 at 2:15 PM MST. The abstract reports durable pgRNA loss in both HBeAg positive and negative patients, supporting a path toward viral cure. PBGENE-HBV targets cccDNA and has FDA Fast Track designation.
neutral 50 · impact 30